Fall 2026

Vascular Product Marketing Intern

Posted on 8/7/2026

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Neurovascular and peripheral medical devices manufacturer

Compensation Overview

$20 - $31/hr

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

In Person

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Word/Pages/Docs
Marketing
Excel/Numbers/Sheets

Get referred to Penumbra Inc

See people who can refer or advise you

Requirements
  • A high school diploma with two or more years of college coursework in biology, neuroscience, business, or a related discipline, plus at least one year of business, administrative, or marketing experience, or an equivalent combination of education and experience.
  • Proficiency with Microsoft Word, PowerPoint, Excel, and other standard office tools.
  • Willingness and ability to work on site.
  • Ability to work in general office, laboratory, and cleanroom environments, with potential exposure to blood-borne pathogens.
  • Ability to lift and move up to 25 pounds and move between buildings and floors.
  • Ability to remain stationary and use a computer or other standard office equipment for extended periods.
  • Ability to read, prepare emails, and produce documents and spreadsheets.
  • Ability to move within the office and access file cabinets or supplies as needed.
  • Ability to communicate and exchange accurate information with employees at all levels on a daily basis.
Responsibilities
  • Assist with planning and execution of ongoing marketing efforts for assigned Penumbra products under direct supervision.
  • Provide administrative support for developing and producing new marketing literature and sales support tools.
  • Assist the Marketing Team in updating the Vascular website.
  • Attend trade shows and meetings to develop an understanding of the clinical use of Penumbra products.
  • Participate in clinical data gathering and review activities, identifying major studies, key endpoints, upcoming trials, and data release dates for Penumbra and competitive products to support publications and scientific presentations that underpin Penumbra’s messages and clinical value propositions in the medical community.
  • Conduct a ShowPad audit and provide recommendations to the team on what should be updated, removed, added, or revamped.
  • Adhere to the Company’s Quality Management System and applicable domestic and global quality system regulations, standards, and procedures.
  • Understand and adhere to applicable security, privacy, and compliance principles, regulations, standards, and procedures.
  • Ensure other members of the department follow the Quality Management System and applicable regulations, standards, and procedures.
  • Perform other work-related duties as assigned.
Desired Qualifications
  • Some exposure to digital marketing.

Penumbra develops and sells medical devices for neurovascular and peripheral vascular conditions. Its products assist doctors in treating stroke and other vascular diseases by delivering—through systems like the Penumbra System and Indigo System—catheters, coils, and evacuation devices that are placed inside blood vessels. The company differentiates itself with a broad, integrated portfolio and a global sales network across Europe and the Americas, emphasizing engineering and clinical performance. Its goal is to improve patient outcomes and sustain growth by investing in ongoing research and development to expand its capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Get referred to Penumbra Inc

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $390 million, rising 14.9% year over year.
  • Magnendo raised $18 million in May 2026 with Penumbra leading the round.
  • STORM-PE and STRIKE-PE strengthen Penumbra's evidence-based push into pulmonary embolism care.

What critics are saying

  • FDA posted a June 2026 RED 68 recall for fracture risk across global lots.
  • Boston Scientific's $14.5 billion acquisition in 2026 freezes Penumbra's independence and retention.
  • Any merger delay or collapse leaves Penumbra exposed to recall scrutiny and valuation compression.

What makes Penumbra Inc unique

  • THUNDERBOLT became the first CAVT stroke platform cleared in the US and Europe.
  • Penumbra's STORM-PE trial outperformed anticoagulation alone for intermediate-high risk pulmonary embolism.
  • Penumbra sells thrombectomy and access devices in 100-plus countries across neurovascular and peripheral care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Jul 30th, 2026
Penumbra reports $390M Q2 revenue, up 14.9% ahead of Boston Scientific acquisition

Penumbra reported second quarter 2026 revenue of $390.0 million, up 14.9% year-over-year. The thrombectomy company's global thrombectomy revenue reached $259.0 million, increasing 12.5%, whilst embolization and access revenue grew 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points from the prior year. Operating income was $41.0 million, with net income of $34.8 million. Total operating expenses stood at $223.9 million, including $6.9 million in acquisition-related costs. Due to Boston Scientific's pending acquisition of Penumbra, the company will not provide full-year 2026 guidance or host a conference call to discuss results. Penumbra operates in over 100 countries, focusing on thrombectomy technologies for conditions including ischaemic stroke and pulmonary embolism.

Business Insider
Jul 24th, 2026
Magnendo raises $18M Series A led by Penumbra to advance magnetic robotic stroke intervention system

Magnendo, an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, has closed an $18 million Series A financing round. The round was led by Penumbra, the thrombectomy company, with participation from new and existing institutional investors. The funding will support productisation of Magnendo's robotic platform and preparation for first-in-human clinical studies. The company's system combines magnetically steerable guidewires with robotic control, medical imaging, and navigation software to help physicians navigate complex vascular anatomy during stroke procedures. Mechanical thrombectomy has transformed acute ischemic stroke treatment, but reaching the treatment site quickly through complex anatomy remains technically demanding. Magnendo's preclinical results suggest the technology could substantially reduce navigation times whilst improving procedural consistency. The company aims to make endovascular procedures faster and more accessible for patients.

Cardiac Vascular News
Jul 24th, 2026
Magnendo secures $18M Series A financing to transform endovascular access for stroke intervention.

Magnendo secures $18M Series A financing to transform endovascular access for stroke intervention. More in financial: Globe Health RSS FeedThis post was originally published on this site NEWTON, Mass., July 24, 2026 (GLOBE NEWSWIRE) - Magnendo Corp., an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, today announced the closing of an $18 million Series A financing led by Penumbra, Inc., the world's leading thrombectomy company, with participation from a syndicate of new and existing institutional investors. The financing will support the productization of Magnendo's robotic platform and preparation for first-in-human clinical studies. Mechanical thrombectomy has transformed the treatment of acute ischemic stroke, yet rapidly reaching the treatment site remains one of the most technically demanding and time-sensitive aspects of the procedure. Navigating from the vascular access site to the clot through complex and often highly tortuous patient anatomy continues to be a major procedural bottleneck, contributing to prolonged procedure times and poorer outcomes in a significant percentage of patients. Magnendo is developing a robotic system that combines magnetically steerable guidewires with robotic control, advanced medical imaging, and intelligent navigation software to improve endovascular access. The system is designed to help physicians navigate complex vascular anatomy more quickly, consistently, and reliably while remaining compatible with existing clinical workflows and commercially available devices. The company has demonstrated encouraging preclinical results in collaboration with leading neurointerventional physicians, showing the potential to substantially reduce navigation times while improving procedural consistency across operators and anatomies. The proceeds from the Series A financing will support the productization of Magnendo's preclinically validated robotic system and magnetic guidewires and advance the company's first clinical platform toward first-in-human studies. "Our mission is to redefine endovascular access through magnetic robotic navigation, enabling physicians to reach the treatment site faster, more reliably, and with greater consistency," said Yoonho Kim, Ph.D., Founder and CEO of Magnendo. "This financing enables us to accelerate the productization of our preclinically validated platform and prepare for first-in-human studies. We are grateful for Penumbra's confidence in our team and look forward to bringing this technology closer to physicians and patients." "Magnendo has developed an elegant and pragmatic approach to one of the most challenging aspects of endovascular intervention," said Shruthi Narayan, President of Penumbra. "We believe the company's focus on improving navigation while integrating into existing clinical workflows has the potential to meaningfully advance neurovascular care, and we are excited to support the team as they move toward clinical translation." About Magnendo Magnendo Corp. is an MIT spinout developing magnetic robotic navigation technology for endovascular intervention. By combining magnetically steerable guidewires with advanced robotics, medical imaging, and intelligent navigation software, Magnendo aims to help physicians reach the treatment site faster, more reliably, and with greater consistency. Its mission is to make life-saving endovascular procedures faster, safer, and more accessible for every patient. For more information, visit www.magnendo.com or connect on LinkedIn. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, CardiacVascularNews support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

MarketBeat
Jul 15th, 2026
Calamos Advisors LLC acquires 62,218 shares of Penumbra, Inc. $PEN.

Calamos Advisors LLC acquires 62,218 shares of Penumbra, Inc. $PEN. July 15, 2026 Key points. * Calamos Advisors LLC dramatically increased its Penumbra stake by 1,334% in Q1, buying 62,218 additional shares and bringing its total holdings to 66,882 shares worth about $21.96 million. * Penumbra reported mixed quarterly results: revenue rose 15.6% year over year to $374.76 million, but EPS of $0.82 missed analyst expectations of $1.06. * Analyst sentiment remains cautious overall, with a Hold consensus rating and an average price target of $360.33, while recent target cuts and downgrades show some division on the stock. * MarketBeat previews the top five stocks to own by August 1st. Calamos Advisors LLC raised its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 1,334.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 66,882 shares of the company's stock after buying an additional 62,218 shares during the period. Calamos Advisors LLC owned about 0.17% of Penumbra worth $21,962,000 at the end of the most recent quarter. Several other institutional investors have also added to or reduced their stakes in PEN. State of Michigan Retirement System boosted its stake in shares of Penumbra by 2.2% during the 1st quarter. State of Michigan Retirement System now owns 9,414 shares of the company's stock worth $3,091,000 after acquiring an additional 200 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Penumbra by 5.1% in the 1st quarter. Principal Financial Group Inc. now owns 88,178 shares of the company's stock worth $28,955,000 after purchasing an additional 4,263 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of Penumbra by 2.4% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 39,003 shares of the company's stock worth $12,807,000 after purchasing an additional 920 shares in the last quarter. Diversify Wealth Management LLC raised its holdings in Penumbra by 72.0% in the 1st quarter. Diversify Wealth Management LLC now owns 8,283 shares of the company's stock worth $2,691,000 after purchasing an additional 3,467 shares during the period. Finally, Citizens Financial Group Inc. RI raised its holdings in Penumbra by 0.3% in the 1st quarter. Citizens Financial Group Inc. RI now owns 31,254 shares of the company's stock worth $10,263,000 after purchasing an additional 88 shares during the period. 88.88% of the stock is currently owned by institutional investors. Penumbra price performance. NYSE:PEN opened at $316.32 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $320.27 and its two-hundred day simple moving average is $329.78. The stock has a market cap of $12.44 billion, a PE ratio of 72.89, a P/E/G ratio of 1.97 and a beta of 0.70. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $362.41. Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). The business had revenue of $374.76 million during the quarter, compared to analysts' expectations of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. Penumbra's revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.83 earnings per share. As a group, analysts forecast that Penumbra, Inc. will post 5.04 EPS for the current fiscal year. Wall Street analyst weigh in. Several analysts have issued reports on the company. Citigroup cut their price target on Penumbra from $374.00 to $350.00 and set a "neutral" rating for the company in a report on Thursday, May 7th. Evercore reaffirmed an "outperform" rating and issued a $320.00 price objective on shares of Penumbra in a research note on Monday, July 6th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Zacks Research cut Penumbra from a "hold" rating to a "strong sell" rating in a research report on Monday, June 29th. Finally, Wall Street Zen upgraded Penumbra to a "hold" rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $360.33. About Penumbra. Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Penumbra, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list. While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

PR Newswire
Jun 15th, 2026
Penumbra secures CE mark for THUNDERBOLT stroke device in Europe

Penumbra has secured CE Mark approval in Europe for THUNDERBOLT, a computer assisted vacuum thrombectomy system for treating acute ischemic stroke. The approval follows US Food and Drug Administration clearance received last week. THUNDERBOLT introduces modulated aspiration technology designed to detect, fatigue and completely remove blood clots at the occlusion site. Powered by Penumbra's ENGINE system, it represents the only CAVT device available for stroke treatment in both Europe and the US. Stroke is the second leading cause of death worldwide, with mortality projected to increase 50% between 2020 and 2050. The device will be pre-packaged with Penumbra's RED catheters. Penumbra is the world's leading thrombectomy company, operating in over 100 countries with a portfolio focused on removing blood clots.